Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 18 Publications

9 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)		 CDK4/CyclinD1 [1]
(Cell-free assay)		 CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NF7NbXNMcW6jc3WgRZN{[Xl? NI\SOFMzPCCq NWXtU3ZjUW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2= MUSyOFY1OTFyMx?=
COLO205 NYrucJhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHHXJBDPzJiaB?= MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=> NYDzSlM5OjR4NEGxNFM>
U937 NE[zPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO3NkBp M3[xNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5zNDFOwG0> NUjrRo9NOjR4NEGxNFM>
MOLM13 M{XOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn4doV5PzJiaB?= M1\ncWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> MkDCNlQ3PDFzMEO=
MOLM13 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWzO|IhcA>? NIjTOI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP NXezXZpNOjR4NEGxNFM>
MDA-MB-435 NHXFNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmyOEBp NFPacmVKSzVyPUCuNVYh|ryP MUOxOVgxOTh|MR?=
K562 MYTDfZRwfG:6aXOgRZN{[Xl? M{TTTVk3KGh? NVXY[|hLTE2VTx?= NGDSOJJKSzVyPUKg{txO MWSyOFQyPzV4Nh?=
DU145 M1e2V2N6fG:2b4jpZ{BCe3OjeR?= M2nhdFk3KGh? NIjEd5BFVVOR NGK1SlFKSzVyPUeuOUDPxE1? NUPleVdoOjR2MUe1OlY>
MDA-MB-231 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PSb|Eh|ryP MUmyOEBp NYfFXnVXTE2VTx?= MlzxR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NEPP[pkzPDRzN{W2Oi=>
MCF7 M1[wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rIbVEh|ryP Ml35NlQhcA>? NVLMUXJkTE2VTx?= MnOwR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NVLUU4tNOjR2MUe1OlY>
MCF7 MojmT4lv[XOnIFHzd4F6 NHvSe3Q2KM7:TR?= MYWyOEBp MVnEUXNQ MmPrTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= NEXwZVAzPDRzN{W2Oi=>
MDA-MB-231 M1nPRmtqdmG|ZTDBd5NigQ>? MnvGOUDPxE1? NWXFdHJJOjRiaB?= Ml7CSG1UVw>? NGrESYhKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw M3TZblI1PDF5NU[2
MDA-MB-231 NIrTO3lHfW6ldHnvckBCe3OjeR?= MlTXNU0yOCEQvF2= NWLCSYNJOjRiaB?= M2XhXGROW09? MnrK[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen NWG5XZJqOjR2MUe1OlY>
MCF7 NUnUcmJzTnWwY4Tpc44hSXO|YYm= NELZZ4UyNTFyIN88US=> NV:3dpkxOjRiaB?= MYPEUXNQ M1vvNYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= MlfPNlQ1OTd3Nk[=
MDA-MB-231 NH\PXo1HfW6ldHnvckBCe3OjeR?= MWCwMlUuOSEQvF2= NX\oNnBpPDhiaB?= NFq0dIlFVVOR Mk\GbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> M{H2VlI1PDF5NU[2
MCF7 NXO4RYxETnWwY4Tpc44hSXO|YYm= M2Xke|AvPS1zIN88US=> NFrPUXg1QCCq NHHkU5JFVVOR MV;oZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> MnTHNlQ1OTd3Nk[=
697 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLiTWM2OD1zNEiuN|ghdk1? M4D2dHNCVkeHUh?=
P12-ICHIKAWA MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu2TWM2OD17Nj6wOEBvVQ>? MYXTRW5ITVJ?
NB69 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXlSIl5UUN3ME2xOlEvQCCwTR?= MYnTRW5ITVJ?
EoL-1 NXjCcYFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK3ZXRRUUN3ME2xPFcvOjZibl2= M1HqT3NCVkeHUh?=
BHT-101 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfZPG1KSzVyPUG5PE4zPSCwTR?= MnzNV2FPT0WU
SK-NEP-1 NEniRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ{MD6wNkBvVQ>? MWPTRW5ITVJ?
MHH-NB-11 NUjNPHBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qxUmlEPTB;MkKwMlE6KG6P MUHTRW5ITVJ?
AsPC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ3Mj61N{BvVQ>? MVjTRW5ITVJ?
ES1 M2HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPPZXpKSzVyPUK1Ok4zPSCwTR?= M{\OTXNCVkeHUh?=
LAMA-84 NEPXOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nob2lEPTB;MkW4MlE6KG6P MYHTRW5ITVJ?
MOLT-16 NFnvb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz6Z3hKUUN3ME2yOVgvPDlibl2= Ml7sV2FPT0WU
ES7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PCfWlEPTB;MkezMlA6KG6P NIPNS|lUSU6JRWK=
KY821 NG\oU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH6folKSzVyPUOxOE4yKG6P NGi1ZYVUSU6JRWK=
RT-112 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\IcFB2UUN3ME2zNlEvODVibl2= M2LufXNCVkeHUh?=
HL-60 NWTTWHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P6bWlEPTB;M{SwMlY3KG6P M2HFUnNCVkeHUh?=
MOLT-4 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH3elVKSzVyPUO0OU4yOyCwTR?= M4LoOHNCVkeHUh?=
KARPAS-45 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTN5Nj6xOkBvVQ>? NI[3SFZUSU6JRWK=
SK-N-AS NVXre2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjoU3JKSzVyPUO4O{45OyCwTR?= NYC1WW0{W0GQR1XS
CTB-1 NFHp[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPSem1CUUN3ME20NFUvODJibl2= M{HCc3NCVkeHUh?=
NKM-1 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm2UGJKSzVyPUSxNU45QSCwTR?= NUK4cJloW0GQR1XS
HTC-C3 NYD1fINMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXEOXBxUUN3ME20N|IvQTVibl2= NVzMc2djW0GQR1XS
BE-13 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR2ND6yO{BvVQ>? M1fDPHNCVkeHUh?=
KOSC-2 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jxcWlEPTB;NE[2Mlkhdk1? NFv1R5NUSU6JRWK=
NB14 NG[wWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTR6Mz61PEBvVQ>? NHfVW3pUSU6JRWK=
CAL-27 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljsTWM2OD12OUSuOVkhdk1? M17wT3NCVkeHUh?=
H9 NGPIb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzuXo16UUN3ME20PVUvPDNibl2= Mm\UV2FPT0WU
RS4-11 M3:4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjsO|llUUN3ME21NFQvPzNibl2= MUTTRW5ITVJ?
PA-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DQZ2lEPTB;NUC5Mlg3KG6P NIDk[|FUSU6JRWK=
MV-4-11 M1vQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTyTWM2OD13MUOuPFUhdk1? NVjpc3QyW0GQR1XS
OS-RC-2 NIrVRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTV{MT62NkBvVQ>? NWH2TVhkW0GQR1XS
RPMI-8226 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13sZmlEPTB;NUK2Mlg3KG6P NY\2cYZ7W0GQR1XS
HGC-27 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rFTmlEPTB;NU[0Mlk6KG6P NYLCbpdmW0GQR1XS
CHP-212 NUn6V2JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jsS2lEPTB;NUmzMlU6KG6P M3ruU3NCVkeHUh?=
NB10 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnIWG1KSzVyPUW5PU4yQCCwTR?= MnTOV2FPT0WU
HH MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PRVGlEPTB;NUm5MlQ{KG6P MVzTRW5ITVJ?
EW-16 NXPIOZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfmNpZKSzVyPU[wN{42OiCwTR?= MnzwV2FPT0WU
ES8 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxSWRCUUN3ME22NFUvOjFibl2= MYXTRW5ITVJ?
HAL-01 M33ndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHzSGlKSzVyPU[wOU43PyCwTR?= MWLTRW5ITVJ?
A204 Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTOXmF3UUN3ME22N|MvQTFibl2= MX\TRW5ITVJ?
MHH-PREB-1 NVPnfnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXGSlNKSzVyPU[zOk46QSCwTR?= M1LWWXNCVkeHUh?=
EM-2 NV\R[otwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDzTWM2OD14NUCuOlQhdk1? NHnwZ|VUSU6JRWK=
BV-173 NI\JR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq4TWM2OD14NUKuOFghdk1? NYDENYlkW0GQR1XS
ONS-76 NF;jN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrUXR2UUN3ME22O|cvQDJibl2= M2HkRXNCVkeHUh?=
KM-H2 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvWTWM2OD14OUWuOVQhdk1? MU\TRW5ITVJ?
D-263MG NXjhZ4ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fRdWlEPTB;N{G3MlEzKG6P M2XIcnNCVkeHUh?=
ES3 NFnw[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3oTWM2OD15MkiuPVMhdk1? NXPTSGR1W0GQR1XS
VA-ES-BJ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr1TWM2OD15M{KuNlchdk1? M{DPdnNCVkeHUh?=
NBsusSR Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTd2Mj65PUBvVQ>? MnHZV2FPT0WU
NCI-H520 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TO[GlEPTB;N{S2MlUzKG6P NIDhdYVUSU6JRWK=
ES5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK1eJFYUUN3ME23OVIvQCCwTR?= NFzhPWFUSU6JRWK=
T-24 NEfEZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULafHZZUUN3ME23O|gvPzFibl2= MmnsV2FPT0WU
SW962 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUexUndwUUN3ME24NFgvPjNibl2= M3fUUHNCVkeHUh?=
EW-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3BTWM2OD16MEiuO|Yhdk1? NH7wUpFUSU6JRWK=
RXF393 NIi5S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P6TWlEPTB;OEGyMlc6KG6P MWnTRW5ITVJ?
U251 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrYTWM2OD16MUOuPFghdk1? NEPaeVhUSU6JRWK=
CAMA-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr6TWM2OD16M{OuPVQhdk1? MULTRW5ITVJ?
JVM-3 NGD5cXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zuc2lEPTB;OEWxMlc5KG6P NWG5W5Q{W0GQR1XS
COLO-800 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXOTWM2OD16OUeuO|ghdk1? M3X3W3NCVkeHUh?=
OVCAR-5 M1XSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjiTWM2OD17MECuNUBvVQ>? NGPTSnJUSU6JRWK=
LB1047-RCC NULaZmlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLTWM2OD17MkeuOVYhdk1? MnX6V2FPT0WU
SW954 M{jMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfGTWM2OD17MkmuOFEhdk1? NHXFbpNUSU6JRWK=
J-RT3-T3-5 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTl|Nj6wOkBvVQ>? MV7TRW5ITVJ?
Mewo MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTl|Nj62JI5O NYnBNoNvW0GQR1XS
NCI-H1770 NUDxd3l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHVUIJIUUN3ME25OFAvPTVibl2= M1jnbHNCVkeHUh?=
HO-1-N-1 NWLmO3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTYTWM2OD17NkKuPFEhdk1? NEeyXXVUSU6JRWK=
HSC-3 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT1bWxIUUN3ME25OlYvPDhibl2= NV2yZpNpW0GQR1XS
TYK-nu MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDsTWM2OD17OUiuNlUhdk1? MlvvV2FPT0WU
KYSE-150 M2[2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvLSoI3UUN3ME2xMlAxODd4IN88US=> MV3TRW5ITVJ?
SN12C MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3JTWM2OD1zLkCwPFc2KM7:TR?= MlvSV2FPT0WU
MOLT-13 NWHH[|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73R2hTUUN3ME2xMlAyPDJzIN88US=> NWjjNolCW0GQR1XS
TE-11 NITJcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwMES4NVIh|ryP MnfOV2FPT0WU
DB NWDUfHJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPvb4pKSzVyPUGuNFczPzNizszN MV\TRW5ITVJ?
CAL-39 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwMEe1NlIh|ryP NEjjSIpUSU6JRWK=
A3-KAW NIrW[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DGTmlEPTB;MT6wPFQxQCEQvF2= MlvkV2FPT0WU
CHP-134 M1\DU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zpeWlEPTB;MT6xNVgxPyEQvF2= M1HWVHNCVkeHUh?=
TGW NXPoTVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jKSmlEPTB;MT6xNlM6PSEQvF2= MlHsV2FPT0WU
QIMR-WIL NHXje5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDrfZpKSzVyPUGuNVMyOzRizszN NInubWlUSU6JRWK=
NCI-SNU-1 M3HxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TldmlEPTB;MT6xOlM2PCEQvF2= M4n5[3NCVkeHUh?=
CGTH-W-1 M1K3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH5TWM2OD1zLkG3NVg3KM7:TR?= NWiyOoZoW0GQR1XS
MHH-ES-1 NUXaOHk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fDT2lEPTB;MT6xO|k5PiEQvF2= MX\TRW5ITVJ?
LB2241-RCC NYDKd5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn1TWM2OD1zLkG4OlIh|ryP MnHJV2FPT0WU
ML-2 M4XVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwMkC3N|Qh|ryP MVjTRW5ITVJ?
COR-L23 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHjTWM2OD1zLkKyPVM{KM7:TR?= M1LTO3NCVkeHUh?=
BFTC-905 M1;PbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwMkSyOlch|ryP NGrZelBUSU6JRWK=
Hs-578-T M1LkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH0[VZKSzVyPUGuNlU5OTdizszN M4G2VXNCVkeHUh?=
KG-1 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPVZZc4UUN3ME2xMlI3Pjh4IN88US=> Mo\YV2FPT0WU
HEL NULtfYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jhSmlEPTB;MT6yPVM{QCEQvF2= MX\TRW5ITVJ?
A549 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyxTWM2OD1zLkK5N|k6KM7:TR?= NWLm[nJlW0GQR1XS
COLO-741 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrZTWM2OD1zLkOyNFg6KM7:TR?= M{nteHNCVkeHUh?=
PC-3 M4HaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rTbmlEPTB;MT6zOVIzOSEQvF2= M17ld3NCVkeHUh?=
HOS NEK4PHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCwcHdKSzVyPUGuN|UzQTZizszN MYXTRW5ITVJ?
HT-1080 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwM{e1NVkh|ryP Ml61V2FPT0WU
TE-8 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[0fmlEPTB;MT60NVc4PCEQvF2= MUfTRW5ITVJ?
BHY NF23[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vFTGlEPTB;MT60OlkzOyEQvF2= NWDBfXJ[W0GQR1XS
BB65-RCC NH\QUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLydFU2UUN3ME2xMlUxPTJ6IN88US=> M1e2UXNCVkeHUh?=
HN NIfafmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;GfYtxUUN3ME2xMlU1ODdzIN88US=> NYq5[4VKW0GQR1XS
NCI-H441 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K2O2lEPTB;MT61OFkxPyEQvF2= NEPGNpJUSU6JRWK=
RPMI-8866 NEW5VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzCXG9KSzVyPUGuOVg2ODdizszN MUfTRW5ITVJ?
CAL-62 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzvdlhKSzVyPUGuOlA5PjJizszN M1j1dXNCVkeHUh?=
MG-63 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW0RYRNUUN3ME2xMlYyQDF|IN88US=> MXLTRW5ITVJ?
SK-LU-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELCS|VKSzVyPUGuOlIyPTJizszN NHnuem9USU6JRWK=
BCPAP M3;SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\WTWM2OD1zLk[2OFU4KM7:TR?= MU\TRW5ITVJ?
22RV1 NXnaOnhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzQW|FKSzVyPUGuOlc5PDNizszN MoL6V2FPT0WU
T47D NYDGOHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj2SG9XUUN3ME2xMlY5ODZzIN88US=> NEC3RXdUSU6JRWK=
MSTO-211H MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7GWItPUUN3ME2xMlY6PjB|IN88US=> NHT3UIlUSU6JRWK=
DEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwN{CyO|Mh|ryP Mlu5V2FPT0WU
H4 NWn2SYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi3VmpKSzVyPUGuO|MzOTJizszN MXfTRW5ITVJ?
CAL-51 M4LUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v6OWlEPTB;MT63OFg2PSEQvF2= NXXaXW45W0GQR1XS
ABC-1 NULCelh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M163OWlEPTB;MT63PFU5OiEQvF2= MVrTRW5ITVJ?
MZ2-MEL NFO0R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwN{m1OFIh|ryP M1\QZXNCVkeHUh?=
YKG-1 M3LJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfBSWJKSzVyPUGuPFExPjFizszN NWroOGM{W0GQR1XS
KM12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwOEG2NFIh|ryP Mk[wV2FPT0WU
L-363 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfrTWM2OD1zLki3OFEzKM7:TR?= MmrtV2FPT0WU
KU812 M3;GSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojjTWM2OD1zLki5NlgzKM7:TR?= NIT1dGpUSU6JRWK=
LOXIMVI M2O0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPHTWM2OD1zLkmxNlI5KM7:TR?= NH\ZNnpUSU6JRWK=
G-401 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnGTWM2OD1zLkmyOFI5KM7:TR?= Moj4V2FPT0WU
SW780 NYnRbIlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHJcXFlUUN3ME2xMlk3OjR4IN88US=> NV:5UFVkW0GQR1XS
SW872 NGC3dmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33CU2lEPTB;MT65PFM{KM7:TR?= MWHTRW5ITVJ?
NB7 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq5TWM2OD1zLkm5N|I{KM7:TR?= NX6xb2s{W0GQR1XS
T98G MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwMEC2OlYh|ryP M1fmenNCVkeHUh?=
SW1710 M{DLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i5ZWlEPTB;Mj6wOlk1PSEQvF2= M1TpfnNCVkeHUh?=
NCI-H1573 M2W3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXxUJNKSzVyPUKuNFczQThizszN M4TxV3NCVkeHUh?=
KE-37 NF\4[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnsOWg2UUN3ME2yMlA5QTVzIN88US=> M4jvZ3NCVkeHUh?=
786-0 NYjpeIdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm2TWM2OD1{LkG1OFM6KM7:TR?= MkXDV2FPT0WU
SAS NI\0VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG3TWM2OD1{LkKwN|c1KM7:TR?= NUfaTWVZW0GQR1XS
CAL-54 NUTROoF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCfmlEPTB;Mj6yNFQyOyEQvF2= NV[yXVZjW0GQR1XS
SF268 M2LGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L6WGlEPTB;Mj6yN|EzOiEQvF2= NVPhbo5nW0GQR1XS
SW620 NWnF[lczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m5OmlEPTB;Mj6yOlE3QSEQvF2= NEDPWpBUSU6JRWK=
MN-60 NF;pepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3kTWM2OD1{LkOxNFYh|ryP MXvTRW5ITVJ?
EFO-27 M{LsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwM{KwOVgh|ryP MWrTRW5ITVJ?
NCI-H747 M2LGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjOOFVkUUN3ME2yMlMzOTl7IN88US=> NH;zVYlUSU6JRWK=
HCC2218 NUfSXoQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;5ToxIUUN3ME2yMlM2Ozd2IN88US=> MlPTV2FPT0WU
MIA-PaCa-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXoPXJKSzVyPUKuN|Y1OzdizszN MYXTRW5ITVJ?
SJSA-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XoT2lEPTB;Mj6zO|c6PiEQvF2= NV\ifpZbW0GQR1XS
RKO NUTOeot3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHwdo5KSzVyPUKuN|g1QTZizszN MoHEV2FPT0WU
NB6 NHL6SoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnVdYR4UUN3ME2yMlQxOzd2IN88US=> M4rQc3NCVkeHUh?=
ES4 NXWwPXVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nIbmlEPTB;Mj60OVQzOiEQvF2= NV\iO2NLW0GQR1XS
EGI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXNTWM2OD1{LkS2PFg{KM7:TR?= NX7NbHdwW0GQR1XS
CTV-1 M4XVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwNUK3O|Mh|ryP M1;uVHNCVkeHUh?=
NCI-H1355 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT5b4xCUUN3ME2yMlU2QTVzIN88US=> MnfNV2FPT0WU
GT3TKB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zTWM2OD1{LkW5NVk6KM7:TR?= M{nPSnNCVkeHUh?=
SK-HEP-1 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYizOFkxUUN3ME2yMlU6OjZ4IN88US=> NEXQblBUSU6JRWK=
GAMG M1;6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXQcJhjUUN3ME2yMlU6Ozl2IN88US=> MWnTRW5ITVJ?
SK-MES-1 NWHGN5VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;hc4tKSzVyPUKuOlE5ODNizszN M1nC[nNCVkeHUh?=
RO82-W-1 NXzBS2VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrVUI5KSzVyPUKuOlIxPTdizszN NWDDToRDW0GQR1XS
ECC10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwN{CyNFYh|ryP NVLlNI5uW0GQR1XS
MCF7 NXjIVFBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJwN{G0OlQh|ryP MWnTRW5ITVJ?
D-283MED MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nFWmlEPTB;Mj63NlQ{KM7:TR?= NUC4UJdRW0GQR1XS
RPMI-7951 NEPBWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXsSoQzUUN3ME2yMlc2Pjl2IN88US=> NFLDOG1USU6JRWK=
Ramos-2G6-4C10 NEPtXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInRb4tKSzVyPUKuO|cxQTlizszN MXLTRW5ITVJ?
KGN MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwOEG4PFQh|ryP M1XibXNCVkeHUh?=
NUGC-3 M2KwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj0Tm9uUUN3ME2yMlgzPTB3IN88US=> NGTHNmRUSU6JRWK=
NCI-H292 NHH1fppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7TTWM2OD1{Lki1NFU{KM7:TR?= Mnr1V2FPT0WU
Becker NV:3eld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwOUW4N|Ih|ryP MYLTRW5ITVJ?
NCI-H1299 NELCZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTNwMEWyOlMh|ryP MmrBV2FPT0WU
ETK-1 NEHV[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULwXoVLUUN3ME2zMlA2PDNizszN MYPTRW5ITVJ?
TK10 NUXRW2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTNwMkCxOlUh|ryP NYnHUXNMW0GQR1XS
VMRC-RCZ NWPNTodPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi3OFdOUUN3ME2zMlM3PDh6IN88US=> Ml7XV2FPT0WU
YH-13 M1XsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m2OmlEPTB;Mz60OFA4QSEQvF2= MoP6V2FPT0WU
DU-145 NEXkWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XSZ2lEPTB;Mz60OlI3QSEQvF2= MmHxV2FPT0WU
SW1088 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnJR2VDUUN3ME2zMlQ4PDdizszN M4X0[HNCVkeHUh?=
HOP-92 M4H3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIThfGNKSzVyPUOuOVA{PDJizszN M2izZnNCVkeHUh?=
KP-N-YS NFvJPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP6TWM2OD1|Lk[yNVM6KM7:TR?= NUHkRZdTW0GQR1XS
NCI-H460 M1HWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;IV5FKSzVyPUOuOlY4OyEQvF2= MlHXV2FPT0WU
U-2-OS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvXTWM2OD1|LkeyOVM2KM7:TR?= MX;TRW5ITVJ?
A101D Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTNwN{[5N|Yh|ryP MkHOV2FPT0WU
MDA-MB-231 NYq3PWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXQTG5KSzVyPUOuPFE6PTFizszN NEfvV5RUSU6JRWK=
IST-MES1 M3;4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLVd5RKSzVyPUOuPFMzKM7:TR?= Ml\PV2FPT0WU
COR-L105 MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XJdWlEPTB;ND6wNVgh|ryP MUHTRW5ITVJ?
NCI-H1437 NY\tUW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRwMEKzNFIh|ryP MoTiV2FPT0WU
CAL-85-1 NHrRN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwMEK0OlEh|ryP M1jpUnNCVkeHUh?=
MZ1-PC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTRwMUi1OVYh|ryP M{\4RXNCVkeHUh?=
VM-CUB-1 M1THfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnSNHpKSzVyPUSuN|EzQDRizszN MlvhV2FPT0WU
CHL-1 NGniTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTRwM{KxOlkh|ryP NU\qdWdrW0GQR1XS
MDA-MB-361 NYTleZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7NTWM2OD12LkOzNVU{KM7:TR?= MmDZV2FPT0WU
NCI-H661 NHW0[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X3UmlEPTB;ND61NFA6OiEQvF2= NGDiNWZUSU6JRWK=
EW-11 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHSTWM2OD12LkWyNlMyKM7:TR?= M4POVXNCVkeHUh?=
BEN M17hRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD4TWM2OD12LkWyPFE2KM7:TR?= MkLhV2FPT0WU
BFTC-909 NGLQOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULnfW5SUUN3ME20MlU3Ojd3IN88US=> NW\TRoFVW0GQR1XS
NCI-H2087 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nOSWlEPTB;ND61PFE3PCEQvF2= M4P3VHNCVkeHUh?=
RVH-421 NVTSWG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTiZnQ1UUN3ME20MlY3PjlizszN M{XDUHNCVkeHUh?=
P30-OHK NX;zU3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rLZmlEPTB;ND62PFAxQCEQvF2= MVrTRW5ITVJ?
NCI-H28 NFLjS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUeyS3ZCUUN3ME20MlgyPjZzIN88US=> NG[xUFBUSU6JRWK=
ES6 MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwOEOwNVYh|ryP M1vXbnNCVkeHUh?=
769-P M4r5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRwOEW5NlYh|ryP MlrLV2FPT0WU
OE33 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTRwOEixOlEh|ryP MlTYV2FPT0WU
SW982 NF;uU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Wx[mlEPTB;ND65OVA3OSEQvF2= MUfTRW5ITVJ?
A388 M{fyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\JTWM2OD13LkCyPVg{KM7:TR?= NUPNcpd5W0GQR1XS
TI-73 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n1UGlEPTB;NT6wOlE6PCEQvF2= MVXTRW5ITVJ?
HCT-116 MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n1cGlEPTB;NT6wPVg5QSEQvF2= MojUV2FPT0WU
HuP-T3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLnTWM2OD13LkG4O|A6KM7:TR?= NIT2eopUSU6JRWK=
G-402 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\tTWM2OD13LkG5OFE3KM7:TR?= MYnTRW5ITVJ?
NCI-H1792 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f1V2lEPTB;NT6yOFYzOiEQvF2= Mn;iV2FPT0WU
NCI-H209 M2PFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LYTGlEPTB;NT6yOVk1OiEQvF2= MVrTRW5ITVJ?
NCI-H1650 M3fGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq3XHFKSzVyPUWuN|A3OzRizszN M2rMOnNCVkeHUh?=
LCLC-97TM1 M2ryUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVwM{G4NFgh|ryP M{jaW3NCVkeHUh?=
S-117 NVG1[ZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTHN|dKSzVyPUWuN|Y6PzZizszN M4TqO3NCVkeHUh?=
GI-ME-N NHLHO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrZUW9mUUN3ME21MlM6PjhzIN88US=> NVu2Nod[W0GQR1XS
NCI-H2122 NEHhSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7O[YdKSzVyPUWuOFk{QTdizszN MUnTRW5ITVJ?
NCI-H1793 NYSySVk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTVwNke1PVMh|ryP NET1ZnNUSU6JRWK=
C2BBe1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j2TWlEPTB;NT63NFA5QCEQvF2= MXXTRW5ITVJ?
TE-12 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrmTm9KSzVyPUWuPFA2PTZizszN M4TxbXNCVkeHUh?=
LCLC-103H M4C5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHKXmp1UUN3ME21MlkyPyEQvF2= M4LaXHNCVkeHUh?=
A673 M1n1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jlR2lEPTB;NT65NVk{OiEQvF2= Mk\5V2FPT0WU
BB30-HNC MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTVwOUizOkDPxE1? M3K3[XNCVkeHUh?=
SF295 MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLGTWM2OD14LkCwOFIzKM7:TR?= NGTCWmtUSU6JRWK=
KU-19-19 NH\pVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fMcWlEPTB;Nj6wNVc{OSEQvF2= M1fxbHNCVkeHUh?=
CFPAC-1 NFTYOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZwMES0OFMh|ryP NULrTIpyW0GQR1XS
LoVo NFf0OnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfle2VKSzVyPU[uNFUxPjNizszN MkjCV2FPT0WU
8505C MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfPXJhKSzVyPU[uNFc2PzNizszN MUHTRW5ITVJ?
GMS-10 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHsXXBKSzVyPU[uNVUxODJizszN MY\TRW5ITVJ?
Ca9-22 NVnMUnRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTsS4tKSzVyPU[uNVY4OSEQvF2= Ml;zV2FPT0WU
DOK NHexdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXziXIZmUUN3ME22MlIzODd{IN88US=> MXHTRW5ITVJ?
FADU MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO3TWM2OD14LkK2NFM6KM7:TR?= NVHNUolIW0GQR1XS
BxPC-3 NIftUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LYV2lEPTB;Nj6yO|MzKM7:TR?= NHvXcHRUSU6JRWK=
CAL-33 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\UTWM2OD14LkK5NlAyKM7:TR?= Ml;XV2FPT0WU
SHP-77 NHfHcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHWXoVKSzVyPU[uN|E2OTJizszN NGPXdFdUSU6JRWK=
LXF-289 NEXQPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHlOVBxUUN3ME22MlM{PDV3IN88US=> MVHTRW5ITVJ?
GB-1 NFr5PJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPZV4lKSzVyPU[uN|gzKM7:TR?= Mlm3V2FPT0WU
KS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLVc5dtUUN3ME22MlM5PDR5IN88US=> NG\WToVUSU6JRWK=
D-502MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\4TWM2OD14LkSyN|c3KM7:TR?= M1z5XXNCVkeHUh?=
LAN-6 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xxb2lEPTB;Nj61NVAzOyEQvF2= M13oe3NCVkeHUh?=
H-EMC-SS NHTwW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfLTWM2OD14LkW2NVQ4KM7:TR?= MVLTRW5ITVJ?
LC-2-ad NFK4dVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nPVmlEPTB;Nj62NFA4PiEQvF2= NUjwdVNoW0GQR1XS
NCI-H1693 NU\qc5BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTZwNkKyNVUh|ryP M1f5fHNCVkeHUh?=
SK-N-FI NVzVeId2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHaW2xKSzVyPU[uO|UxPDRizszN M1fUPHNCVkeHUh?=
D-423MG NVfFbWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C2NmlEPTB;Nj63OlEyPyEQvF2= MX;TRW5ITVJ?
KNS-42 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSzTWM2OD14Lke4NVk4KM7:TR?= MlPVV2FPT0WU
GCT MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fH[2lEPTB;Nj65N|gh|ryP MYjTRW5ITVJ?
DSH1 NGrjTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPWb3dZUUN3ME23MlA3OzNizszN NFvWRYFUSU6JRWK=
D-247MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jRe2lEPTB;Nz6wO|g5OSEQvF2= NH;sTW1USU6JRWK=
NCI-SNU-5 NHX3SHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDmcJM{UUN3ME23MlE5OzdzIN88US=> NF;mdmFUSU6JRWK=
TE-6 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrCSY51UUN3ME23MlIxPjBzIN88US=> MojtV2FPT0WU
NOMO-1 NYX0bFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TMWGlEPTB;Nz6yNlEzPyEQvF2= NEO3NXpUSU6JRWK=
NB17 NEfYfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPpTWM2OD15LkOwN|A6KM7:TR?= NU\j[IdTW0GQR1XS
EW-22 NFLqZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W4ZWlEPTB;Nz6zOFM1QCEQvF2= NEG5N3NUSU6JRWK=
EW-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPVS|JKSzVyPUeuN|UyPjJizszN NInkToVUSU6JRWK=
DOHH-2 NVnUbG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTYcZJWUUN3ME23MlQ1ODJizszN MVfTRW5ITVJ?
TGBC1TKB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDZZYJyUUN3ME23MlQ6QDl7IN88US=> MVrTRW5ITVJ?
GR-ST NGfNU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXyxRYR1UUN3ME23MlUzPTl2IN88US=> NVHsTm83W0GQR1XS
KYSE-520 M4fVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HwXGlEPTB;Nz61OVUyPSEQvF2= NH3Xd5BUSU6JRWK=
CAPAN-1 M4jHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTdwNUm1NUDPxE1? Mn:yV2FPT0WU
HCE-4 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXnVVlPUUN3ME23MlYzOjd7IN88US=> NIC0Z|VUSU6JRWK=
MLMA MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV63N4VmUUN3ME23MlYzQTV5IN88US=> NFHifWhUSU6JRWK=
HT-144 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXY[3I2UUN3ME23MlY2OzZ6IN88US=> MX\TRW5ITVJ?
KYSE-180 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ZbmlEPTB;Nz63NVE3QSEQvF2= MX7TRW5ITVJ?
TE-5 M1ToW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL5TWM2OD15Lkm1PVcyKM7:TR?= NFn1UYJUSU6JRWK=
IGROV-1 NFHxU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS2dZgyUUN3ME23Mlk5PTVzIN88US=> MVXTRW5ITVJ?
NCI-H1581 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVviOZM{UUN3ME24MlAyOiEQvF2= MXzTRW5ITVJ?
SW1990 NUPXWIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW0TWM2OD16LkC0OlU6KM7:TR?= MoXxV2FPT0WU
EFM-19 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHafIZrUUN3ME24MlA5PTR3IN88US=> MkTtV2FPT0WU
OGR-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3JWWl6UUN3ME24MlQ{ODJ|IN88US=> M1zWcnNCVkeHUh?=
U-118-MG NVfve49zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjISGc2UUN3ME24MlQ{PDZ|IN88US=> NWCzU4xlW0GQR1XS
SK-OV-3 M3HzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfjPFZKSzVyPUiuOFY4PjVizszN NXix[Xd6W0GQR1XS
KNS-62 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjRTWM2OD16LkWxO|YyKM7:TR?= NHXQ[pZUSU6JRWK=
GOTO MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PSW2lEPTB;OD61O|Y{PSEQvF2= NILV[lJUSU6JRWK=
8305C MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRThwN{C0PFQh|ryP NEXiPIRUSU6JRWK=
RPMI-2650 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjpS5pKSzVyPUiuO|E6PTVizszN MXzTRW5ITVJ?
NEC8 Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV65S2FbUUN3ME24Mlc1OzB5IN88US=> NGToPVJUSU6JRWK=
KYSE-450 NEHZV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPDUGtCUUN3ME24Mlg3PTR6IN88US=> NVzFdHQ{W0GQR1XS
RMG-I NUHkUVlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCwdmx{UUN3ME25MlE1ODV6IN88US=> NWnIXoJ4W0GQR1XS
CAKI-1 NIryS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTpbldkUUN3ME25MlMyQTd7IN88US=> NHTodmhUSU6JRWK=
KYSE-510 M{LIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLsOmZKSzVyPUmuN|U4PzhizszN M1nkdHNCVkeHUh?=
A4-Fuk NX7xTmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjkTmFKSzVyPUmuN|Y4ODFizszN MUTTRW5ITVJ?
AN3-CA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjzU|VKSzVyPUmuOFU1PDRizszN M{XmTXNCVkeHUh?=
SK-N-DZ NWTVdGl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlToTWM2OD17LkeyPFQ6KM7:TR?= NWLaW|V3W0GQR1XS
HSC-2 NGTWWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nYZmlEPTB;OT63OlYzQSEQvF2= NGHP[4VUSU6JRWK=
EW-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTKbWh1UUN3ME25Mlc6OzZ7IN88US=> M2rsZ3NCVkeHUh?=
D-566MG MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTlwOEO2OlQh|ryP M{DuS3NCVkeHUh?=
COLO-792 NFHXZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf2T3dmUUN3ME25Mlk5PzR4IN88US=> Ml\tV2FPT0WU
TE-10 M{\zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFyLkCzPVYh|ryP NWTXfWZ3W0GQR1XS
NCI-H650 M4TufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFyLkSyPFYh|ryP NIXYdnRUSU6JRWK=
U-266 NGfpbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli5TWM2OD1zMD60OVUh|ryP NYH2bmlOW0GQR1XS
Detroit562 M2TyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzrSWJIUUN3ME2xNU4xPTF3IN88US=> M2j0NHNCVkeHUh?=
NH-12 NXvSXplyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjGN|cyUUN3ME2xNU4yPDR4IN88US=> M4nFOHNCVkeHUh?=
CO-314 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXNGtkUUN3ME2xNU4zQDR{IN88US=> M{TKWXNCVkeHUh?=
IST-MEL1 NYrJTVY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHUO2ZWUUN3ME2xNU42OzJ|IN88US=> MWXTRW5ITVJ?
KNS-81-FD NEftfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFzLkW1Nlch|ryP Mlf2V2FPT0WU
SW1463 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fRcWlEPTB;MUGuOVk5QSEQvF2= MYDTRW5ITVJ?
NCI-H23 M3PJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnCTWM2OD1zMT62OVUzKM7:TR?= NEfk[FNUSU6JRWK=
SK-MEL-2 M37uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXOTWM2OD1zMT63NVk4KM7:TR?= NYnSNJBqW0GQR1XS
NB13 M3;zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF{LkG0PVUh|ryP MXnTRW5ITVJ?
Daoy M2C5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjBeJZKSzVyPUGyMlI5PTZizszN NHXiS2JUSU6JRWK=
NCI-H1623 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrBXXh3UUN3ME2xNk4{QDBzIN88US=> NIj4ZXdUSU6JRWK=
NMC-G1 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF{LkexO{DPxE1? MWHTRW5ITVJ?
DK-MG M4\6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXriNHhjUUN3ME2xNk46PDh{IN88US=> M2fBfXNCVkeHUh?=
TCCSUP M1qwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF|LkGyPFQh|ryP NV:xTY04W0GQR1XS
SCC-15 NWjFdo1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17zSmlEPTB;MUOuNlY2OSEQvF2= NVPq[GpYW0GQR1XS
NOS-1 NV7TUnBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF|LkK4PVMh|ryP M2HU[3NCVkeHUh?=
RH-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[0TWM2OD1zMz6zNFM4KM7:TR?= MnfDV2FPT0WU
SK-MEL-3 M365fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj1TWM2OD1zMz6zO|I5KM7:TR?= MXXTRW5ITVJ?
NB5 M2Hkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WyW2lEPTB;MUOuOFA3PyEQvF2= MVHTRW5ITVJ?
SNU-387 NXnIUpJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF|LkWwO|Ih|ryP NVfIdlZGW0GQR1XS
CAL-120 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzZc5VKSzVyPUGzMlY4OThizszN M33EcXNCVkeHUh?=
Mo-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[yTWM2OD1zMz63NFch|ryP MWLTRW5ITVJ?
LNCaP-Clone-FGC M4Kze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF|Lke5PVIh|ryP NUDrcXhLW0GQR1XS
CAN NFLZdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37GWGlEPTB;MUSuNFI5QCEQvF2= M3fkOHNCVkeHUh?=
SK-MEL-30 NX2z[VQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTHTWM2OD1zND6wOlMh|ryP NGLKdlRUSU6JRWK=
COLO-678 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXlTWM2OD1zND6wPFIzKM7:TR?= NGC5cmlUSU6JRWK=
SCC-9 NGfzTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjQTWM2OD1zND6xNFIyKM7:TR?= Mk\1V2FPT0WU
KINGS-1 NIjxbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjIfXBrUUN3ME2xOE4yPDB{IN88US=> MWnTRW5ITVJ?
SL-513 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK4TWM2OD1zND6xPFch|ryP MVXTRW5ITVJ?
HLE NYDRXY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrvT2hWUUN3ME2xOE4{QDV{IN88US=> Mn;rV2FPT0WU
SW1573 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF2LkS0N|Uh|ryP MlrDV2FPT0WU
KYSE-140 NU\5SmpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOwTWM2OD1zND62N|I4KM7:TR?= NX3MNFRxW0GQR1XS
SK-PN-DW NHXGTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXoSmZKSzVyPUG0MlgxODFizszN MXfTRW5ITVJ?
A253 NHvhU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ZTWM2OD1zNT6wOlI2KM7:TR?= M4PYXXNCVkeHUh?=
CAL-12T MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF3LkS2OlIh|ryP MlzhV2FPT0WU
COLO-679 M2S4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF3Lke2PFMh|ryP MULTRW5ITVJ?
UACC-257 NYrBVHVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XXeWlEPTB;MU[uNVIxOSEQvF2= NWLmdItzW0GQR1XS
U-87-MG NEHsOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF4LkO1NlMh|ryP NGPUcpJUSU6JRWK=
HCC1806 NYrzdWFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF4LkewO|Eh|ryP NEXtZoZUSU6JRWK=
NCI-H2170 NGP2bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PaRWlEPTB;MUeuNlQ1QCEQvF2= MULTRW5ITVJ?
AGS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF5LkO4NFgh|ryP NFrWOotUSU6JRWK=
MEL-HO NWTESFA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\xS|ZKSzVyPUG3Mlc2ODNizszN M323cXNCVkeHUh?=
SW48 M{nPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF5Lke3NVYh|ryP NX\vSYtOW0GQR1XS
HuP-T4 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjHU|FEUUN3ME2xPE4xOjB4IN88US=> NIi4eJJUSU6JRWK=
NCI-H720 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;kdmlEPTB;MUiuNVQxOiEQvF2= NF7TfodUSU6JRWK=
RCC10RGB MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGwWVlTUUN3ME2xPE4yPjl5IN88US=> NGfFdmFUSU6JRWK=
HD-MY-Z MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvMSXNKSzVyPUG4MlIzPTRizszN NUDCVVhkW0GQR1XS
A427 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Xv[2lEPTB;MUiuOVA6PCEQvF2= NHzT[YJUSU6JRWK=
HCC2998 NH;xO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF6Lk[wOVEh|ryP NHXHPGNUSU6JRWK=
EPLC-272H MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnyWoVKSzVyPUG5MlA1OzRizszN M2LtOXNCVkeHUh?=
C32 M1nqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF7LkC0OUDPxE1? NIHJOVhUSU6JRWK=
UMC-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHBVGFKSzVyPUG5MlIyOjNizszN MXfTRW5ITVJ?
CaR-1 NFTVTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DGcWlEPTB;MUmuOlgxPCEQvF2= NFz0SJJUSU6JRWK=
KYSE-410 NUj2S29bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF7LkmxN|kh|ryP MUHTRW5ITVJ?
HuCCT1 NVXwRnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTqbXh4UUN3ME2yNE43Ojl2IN88US=> NHzvVmNUSU6JRWK=
LB996-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWriUFdRUUN3ME2yNE44OTZ6IN88US=> NVrBdZpDW0GQR1XS
KYSE-70 M1K5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7VWYVKSzVyPUKwMlgxPTlizszN M4n5UnNCVkeHUh?=
CAL-72 M1PWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT5TWM2OD1{MD65NVUh|ryP NEe3[25USU6JRWK=
Capan-2 NHvuVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH4eVZKSzVyPUKxMlA1OTNizszN MXLTRW5ITVJ?
PANC-08-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJzLkK1NVUh|ryP M1TzdnNCVkeHUh?=
SBC-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3RfIxKSzVyPUKxMlMxQDFizszN MlPwV2FPT0WU
MFM-223 NIXVV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULM[ZpRUUN3ME2yNU4{OzR{IN88US=> M33W[XNCVkeHUh?=
BB49-HNC NFLmbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4c44yUUN3ME2yNU42PzF4IN88US=> NHG4[3lUSU6JRWK=
SH-4 M{jjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXJNG9xUUN3ME2yNU43PjF6IN88US=> M1LTSnNCVkeHUh?=
HuO9 NVW0PIhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJzLkm4NlUh|ryP M4ezSHNCVkeHUh?=
AM-38 NFLHV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17kZmlEPTB;MkKuNFQ5PSEQvF2= M131SHNCVkeHUh?=
A431 M2T1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO5TWM2OD1{Mz6yNVE6KM7:TR?= MV3TRW5ITVJ?
YAPC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjRWY1FUUN3ME2yN{4zPjVzIN88US=> NHO4N4VUSU6JRWK=
LU-139 M1j6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnGSoF{UUN3ME2yN{41QDB7IN88US=> MVHTRW5ITVJ?
HEC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ|LkS5N|ch|ryP Ml7iV2FPT0WU
SCC-25 NXTCTYl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvZRZhKSzVyPUK0MlMxODZizszN M2DJUnNCVkeHUh?=
HT-29 NFfie4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ2LkO4NlMh|ryP NH3z[pdUSU6JRWK=
PC-14 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe3fGtKSzVyPUK0MlY2PzFizszN MmLGV2FPT0WU
Calu-6 M{nyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\sWnNKSzVyPUK1MlUxPzFizszN NES2copUSU6JRWK=
SJRH30 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KyZWlEPTB;MkWuOlQ6PiEQvF2= M1PEVnNCVkeHUh?=
ChaGo-K-1 NY\GdJk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjMdlFwUUN3ME2yOk4yPjJ7IN88US=> MoDSV2FPT0WU
IA-LM NXLxS5p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnVdJFKSzVyPUK2MlM3PDVizszN MVjTRW5ITVJ?
GP5d M1:yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjWTWM2OD1{Nj60OFkyKM7:TR?= NUnaWoI1W0GQR1XS
NCI-H2291 M4C3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ4Lk[1OFEh|ryP NHq0W2VUSU6JRWK=
BALL-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXGTWM2OD1{Nj65N|k4KM7:TR?= NYfmb4ZUW0GQR1XS
HCC1954 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2Umt2UUN3ME2yOk46QDB6IN88US=> Mny4V2FPT0WU
NCI-H2452 NGnncFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELH[G1KSzVyPUK3MlQyPjNizszN NWfaVohOW0GQR1XS
LU-99A NXHRO4c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojaTWM2OD1{Nz61OVgzKM7:TR?= MXHTRW5ITVJ?
NTERA-S-cl-D1 M1nvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ThVWlEPTB;MkeuO|I6QSEQvF2= M3PRW3NCVkeHUh?=
PANC-10-05 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnqTWM2OD1{Nz63O|c2KM7:TR?= M3fieHNCVkeHUh?=
NCI-H2405 NGq4eIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrNTWM2OD1{Nz65N|g4KM7:TR?= NYK4RZdGW0GQR1XS
MDA-MB-415 NVrzU25CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnMTWM2OD1{OD60NVM4KM7:TR?= NXva[mxLW0GQR1XS
NCI-H2342 NV7UXVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnGbHdFUUN3ME2yPE42OjhzIN88US=> Ml\3V2FPT0WU
TGBC24TKB Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELST4hKSzVyPUK4MlcyOTdizszN MoKyV2FPT0WU
LU-134-A M2G1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXKTWM2OD1{OD65NlYyKM7:TR?= NXqxVoxUW0GQR1XS
SCC-4 NWnGUWJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnRTWM2OD1|MT6wOFk1KM7:TR?= MYXTRW5ITVJ?
Saos-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnhTWM2OD1|MT65N|A3KM7:TR?= MU\TRW5ITVJ?
RERF-LC-MS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN{LkiyN|Eh|ryP M1LITXNCVkeHUh?=
M14 M3nufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\NeYpKSzVyPUOyMlk4PjRizszN NF62U5FUSU6JRWK=
HPAF-II NWfuO|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjpUXNKSzVyPUOzMlUxOTFizszN MYTTRW5ITVJ?
NCI-H1755 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDYSpFWUUN3ME2zOE4{OzB3IN88US=> MVfTRW5ITVJ?
D-392MG NFLHbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXy[|VKSzVyPUO1Mlg3PzRizszN NUDqXHdpW0GQR1XS
A704 NVuxNppET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTPRZpKSzVyPUO2MlA1OjdizszN NV\zNnlWW0GQR1XS
CP50-MEL-B MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn4U2RKSzVyPUO2MlE6OTFizszN NVXMc45XW0GQR1XS
EW-18 NX\EcIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;yfGlEPTB;M{[uOFUzKM7:TR?= NHzIZXpUSU6JRWK=
WM-115 M1vOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfRTWM2OD1|Nj64NFk6KM7:TR?= NWjONXRMW0GQR1XS
LU-65 MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XyVWlEPTB;M{euNVQyPyEQvF2= M3PuUnNCVkeHUh?=
NCI-H1563 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjVVnBKSzVyPUO3MlI1QDRizszN MVjTRW5ITVJ?
DBTRG-05MG M3uwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTETWM2OD1|OD6wOlkyKM7:TR?= MYTTRW5ITVJ?
NCI-H630 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzRPYp4UUN3ME2zPE41PzF2IN88US=> NV\abFlUW0GQR1XS
NCI-H1155 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrRTpdKSzVyPUO5MlI1OiEQvF2= MXHTRW5ITVJ?
OVACR-3 M2fPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPp[GhKSzVyPUO5MlkyQTVizszN NFvO[JFUSU6JRWK=
OAW-42 M3y4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi0TWM2OD12MD60NlU5KM7:TR?= NF\LRYpUSU6JRWK=
JVM-2 NHrCemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTaTWM2OD12MT6yOFE2KM7:TR?= M2nx[HNCVkeHUh?=
C3A MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WzZmlEPTB;NEGuN|Q1PyEQvF2= Ml3VV2FPT0WU
HT55 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KxeGlEPTB;NEKuNlg1OSEQvF2= MVrTRW5ITVJ?
OVCAR-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PQVmlEPTB;NEKuNlk4PCEQvF2= MnPGV2FPT0WU
MEG-01 M13oWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL4bJByUUN3ME20Nk41PjF4IN88US=> MnTRV2FPT0WU
NCI-H82 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR|Lkm4PVIh|ryP NGLZV4VUSU6JRWK=
JEG-3 NXznfYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK0TWM2OD12ND65OFch|ryP NX\DTm9OW0GQR1XS
BPH-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jBeGlEPTB;NE[uN|k6QCEQvF2= MWjTRW5ITVJ?
MPP-89 MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\oVWdVUUN3ME20O{4zQDl6IN88US=> NYTndoJMW0GQR1XS
ALL-PO MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz1UYxKSzVyPUS3MlQyQDhizszN MVvTRW5ITVJ?
HT MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e0UWlEPTB;NEeuOFkzKM7:TR?= MVLTRW5ITVJ?
NCI-H2347 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\STWM2OD12OD6wO|E2KM7:TR?= Ml\FV2FPT0WU
A2780 NX;OOIF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG1TWM2OD12OT60NlI5KM7:TR?= NUXndHBHW0GQR1XS
KARPAS-299 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\iOog{UUN3ME20PU42OTF7IN88US=> NV7uZVB[W0GQR1XS
NCI-H1651 NFTqNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfwTWM2OD12OT64PFIyKM7:TR?= NYToTVB7W0GQR1XS

... Click to View More Cell Line Experimental Data
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing. 		6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl
CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer January 7 2019 Phase 2
NCT03691493 Not yet recruiting Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 Emory University|Pfizer December 1 2018 Phase 2
NCT03530696 Not yet recruiting HER2-positive Breast Cancer|Breast Cancer|Breast Cancer Stage|Recurrent Breast Cancer|Metastatic Breast Cancer|HER2 Positive Breast Carcinoma University of Arizona|Pfizer November 30 2018 Phase 2
NCT03531645 Not yet recruiting Malignant Neoplasms of Female Genital Organs M.D. Anderson Cancer Center|AstraZeneca|Pfizer November 2018 Phase 2
NCT03644186 Not yet recruiting Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer International Breast Cancer Study Group|Pfizer|Hoffmann-La Roche October 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

  • Most Potent CDK Inhibitor

    LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products3

  • SU9516 New

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A New

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib mesylate (LY2835219)

    abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID